Rockefeller University Research: Arginine Levels Control Immune Response
Arginine availability controls whether the immune system can recognize colon cancer cells and viral infections, according to research published in the journal Cell.
- Cellular equipment struggles to build key immune proteins when arginine levels run low.
- Supplying moderate amounts of arginine restored production of MHC-1 proteins in laboratory tests.
- Dietary arginine reduced tumor formation and lessened influenza and SARS-CoV-2 severity in mice.
Scientists at Rockefeller University found that when the body runs low on this amino acid, a key part of its immune defense system stops working properly. Arginine is an amino acid produced naturally by the body and obtained from protein-rich foods to build vital proteins.
Unusually low arginine levels are associated with several diseases, including colon cancer. The new research clarifies how this shortage affects the body’s defenses by disrupting the production of MHC-1 proteins, which act as a warning system to help immune cells identify cancerous changes and viral infections.
Cellular Ribosomes Stall Without Amino Acid
Researchers examined the effects of arginine availability across disease models including colon cancer, influenza, and SARS-CoV-2. Arginine emerged as the most depleted amino acid across all of these conditions.
When arginine became scarce, cells struggled to produce enough of the MHC-1 protein. Because the proteins involved in MHC-1 production require arginine at numerous points, ribosomes stalled while trying to manufacture them, preventing molecular warning signals from reaching the cell surface.
Supplying a moderate amount of arginine, comparable to the quantity in a couple of over-the-counter supplement tablets, helped restore production of this protein. Researchers learned in 2023 that starving colon cancer cells of arginine led them to build up a higher frequency of genetic mutations.
Dietary Adjustments Alter Mouse Disease Outcomes
Mice receiving diets low in arginine developed more colon cancer tumors, while mice consuming higher amounts developed fewer tumors. The research was supported in part by the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at The Rockefeller University and the Weill Cancer East Hub.
Additional experiments in mouse models of influenza and SARS-CoV-2 showed similar patterns. Mice consuming more arginine experienced less severe symptoms from viral infections.
“Not only did mice with an arginine-rich diet have milder symptoms from viral infections, giving the mice arginine after influenza infection improved their outcomes too,” said Qiushuang Wu, a postdoc in the lab.
Human Research Must Determine If Arginine Benefits People
The findings raise the possibility that an inexpensive supplement could eventually become a useful addition to cancer treatments and viral infection strategies. Yet, scientists still need to perform additional studies involving humans to verify if the positive effects seen in mice will successfully become practical therapies for people.
“Arginine supplementation could be readily tested in patients receiving immunotherapies or given to high-risk populations exposed to viral pathogens,” said Sohail Tavazoie, who directs the Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology at Rockefeller University.
“Considering that arginine is inexpensive and readily available, we hope that therapeutic and preventative studies could be undertaken soon,” Tavazoie added.
As researchers investigate whether dietary manipulation impacts other amino acids in various disease contexts, patients managing complex immune or oncological conditions should consult qualified clinical specialists regarding appropriate nutritional and therapeutic strategies.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Worth a look